64Cu-NCAB-001

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug Name64Cu-NCAB-001

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJapan Agency For Medical Research And Development

China Registration ClassN/A

Develop Information

Active CompaniesJapan Agency For Medical Research And Development

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A